Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis
ConclusionsThe survival benefits of PD-1 monotherapy for high expression with PD-L1 immunohistochemistry testing are inferior to those of PD-1 combined with chemotherapy without testing, but it is found to be more cost-effective at the WTP thresholds in China and holds great potential in increasing affordability and reducing the economic burden. (Source: BioDrugs)
Source: BioDrugs - October 4, 2023 Category: Drugs & Pharmacology Source Type: research
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
ConclusionsThese findings suggest that bevacizumab-awwb is as effective and safe as bevacizumab reference product for the real-world treatment of mCRC. (Source: BioDrugs)
Source: BioDrugs - September 25, 2023 Category: Drugs & Pharmacology Source Type: research
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
ConclusionsIXEQ4W was associated with rapid and significant improvements in the signs and symptoms of active r-axSpA in Chinese patients at week 16 that were sustained at week 52, with no new safety signals.Trial registration numberClinicalTrials.gov identifier: NCT04285229. (Source: BioDrugs)
Source: BioDrugs - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Malaria Vaccines: Progress to Date
AbstractMalaria is a mosquito-borne disease caused by protozoan parasites of the genusPlasmodium. Despite significant declines in malaria-attributable morbidity and mortality over the last two decades, it remains a major public health burden in many countries. This underscores the critical need for improved strategies to prevent, treat and control malaria if we are to ultimately progress towards the eradication of this disease. Ideally, this will include the development and deployment of a highly effective malaria vaccine that is able to induce long-lasting protective immunity. There are many malaria vaccine candidates in ...
Source: BioDrugs - September 20, 2023 Category: Drugs & Pharmacology Source Type: research
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical
AbstractOver the past few years, there has been a surge in the industrial production of recombinant enzymes from microorganisms due to their catalytic characteristics being highly efficient, selective, and biocompatible.l-asparaginase (l-ASNase) is an enzyme belonging to the class of amidohydrolases that catalyzes the hydrolysis ofl-asparagine intol-aspartic acid and ammonia. It has been widely investigated as a biologic agent for its antineoplastic properties in treating acute lymphoblastic leukemia. The demand forl-ASNase is mainly met by the production of recombinant type IIl-ASNase fromEscherichia coli andErwinia chrys...
Source: BioDrugs - September 12, 2023 Category: Drugs & Pharmacology Source Type: research
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials
ConclusionsIntravitreal anti-VEGF drugs were not associated with an acute kidney injury risk, regardless of which anti-VEGF drugs (aflibercept or ranibizumab) or retinal diseases (age-related macular degeneration, diabetic retinopathy/diabetic macular edema, or retinal vein occlusion) were involved.Systematic Review Protocol RegistrationPROSPERO CRD42021267854. (Source: BioDrugs)
Source: BioDrugs - September 7, 2023 Category: Drugs & Pharmacology Source Type: research
Patients ’ Perceptions of Biosimilars: A Systematic Review
ConclusionsThe majority of patients expressed satisfaction with treatment using biosimilars, but limited knowledge continued to impede their perceptions. Doubts about the clinical effects and regulatory approval pathway were identified as major factors that negatively influenced patients ’ attitudes towards biosimilars, while the impact of a price advantage was mixed. It is essential to maintain a focus on educating healthcare professionals about biosimilars, including their clinical outcomes and the regulatory pathway, which equips them to provide comprehensive and informed guida nce to patients. (Source: BioDrugs)
Source: BioDrugs - September 7, 2023 Category: Drugs & Pharmacology Source Type: research
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials
ConclusionsIntravitreal anti-VEGF drugs were not associated with an acute kidney injury risk, regardless of which anti-VEGF drugs (aflibercept or ranibizumab) or retinal diseases (age-related macular degeneration, diabetic retinopathy/diabetic macular edema, or retinal vein occlusion) were involved.Systematic Review Protocol RegistrationPROSPERO CRD42021267854. (Source: BioDrugs)
Source: BioDrugs - September 7, 2023 Category: Drugs & Pharmacology Source Type: research
Patients ’ Perceptions of Biosimilars: A Systematic Review
ConclusionsThe majority of patients expressed satisfaction with treatment using biosimilars, but limited knowledge continued to impede their perceptions. Doubts about the clinical effects and regulatory approval pathway were identified as major factors that negatively influenced patients ’ attitudes towards biosimilars, while the impact of a price advantage was mixed. It is essential to maintain a focus on educating healthcare professionals about biosimilars, including their clinical outcomes and the regulatory pathway, which equips them to provide comprehensive and informed guida nce to patients. (Source: BioDrugs)
Source: BioDrugs - September 7, 2023 Category: Drugs & Pharmacology Source Type: research
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune ‐Mediated Inflammatory Disease
ConclusionsWith the exception of female sex in RA, axSpA, and CD, none of the candidate predictors were associated with SB5 discontinuation. Persistence on SB5 was high, treatment effectiveness was maintained, and no safety signals were detected.Trial RegistrationThis trial is registered with ClinicalTrials.gov: NCT04089514. (Source: BioDrugs)
Source: BioDrugs - August 26, 2023 Category: Drugs & Pharmacology Source Type: research
